TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01196871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Beta
Description: IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Beta
Description: IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Beta
Description: IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Beta
Description: IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Alfa
Description: IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Alfa
Description: IV infusion, single dose
Study: NCT01527916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: low dose, middle dose, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: low dose, middle dose, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: low dose, middle dose, high dose
Study: NCT03678181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Resources
Description: The investigators will provide a HIV-related content as the attention-control condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Resources
Description: The investigators will provide a HIV-related content as the attention-control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Resources
Description: The investigators will provide a HIV-related content as the attention-control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The investigators will provide evidence-based answers to users' health questions, including linkage to care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The investigators will provide evidence-based answers to users' health questions, including linkage to care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing
Description: The investigators will provide opportunities for participants to get tested through HIV home test kits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Testing
Description: The investigators will provide opportunities for participants to get tested through HIV home test kits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing
Description: The investigators will provide opportunities for participants to get tested through HIV home test kits.
Study: NCT01079234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily
Study: NCT01550354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of propofol
Description: intravenous administration of propofol 2 mg/kg before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of alfentanil
Description: intravenous administration of alfentanil 14 μg/kg before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of rocuronium
Description: Intravenous administration of rocuronium 0.3 mg/kg before intubation
Study: NCT02791009

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Study: NCT03253601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strategy Training
Description: Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
Study: NCT02791009

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Study: NCT03253601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
Study: NCT00713830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT01079234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine injected subcutaneously (under the skin) once daily
Study: NCT00713830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT01079234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: At least three daily doses at meal-time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: At least three daily doses at meal-time
Study: NCT00713830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study: NCT01079234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: At least three daily doses at meal-time
Study: NCT03873051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenge-Focused Program
Description: Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewards-Focused Program
Description: Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
Study: NCT03001895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT
Description: 18F-DCFPyL PET/CT
Study: NCT00713830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
Study: NCT01312961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, one subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dupilumab)
Description: Solution for injection, one subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol combination therapy
Description: Oral inhalation twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone/Salmeterol combination therapy
Description: Oral inhalation twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone monotherapy
Description: Oral inhalation twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone monotherapy
Description: Oral inhalation twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Oral inhalation as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: Oral inhalation as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: Oral inhalation as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol
Description: Oral inhalation as needed.
Study: NCT03511482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myAsthma Application
Description: myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lloyds Pharmacy Online Doctor
Description: Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare.
Study: NCT02709070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection
Description: hepatectomy for HCC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection
Description: hepatectomy for HCC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: highly-purified CTL
Description: hepatectomy first, followed by highly-purified CTL treatment
Study: NCT03509948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine 1.5 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine 1.5 mg film-coated tablets
Study: NCT03519230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib capsule
Description: 60 mg twice daily (BID), orally (per os-PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 60mg BID, PO
Study: NCT04208412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: KVD900 tablet 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: KVD900 tablet 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: KVD900 tablet 600 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: KVD900-matched Placebo Tablet
Study: NCT04211688

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Schema therapy
Description: Bimonthly outpatient psychotherapy delivered in individual setting
Study: NCT04177173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: improvement of disease activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate 10 mg
Description: improvement of disease activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate 10 mg
Description: improvement of disease activity
Study: NCT03300726

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF analysis
Description: CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF analysis
Description: CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
Study: NCT04211688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Schema therapy
Description: weekly outpatient psychotherapy delivered in group setting
Study: NCT01900769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood Volume Dilution
Study: NCT01320995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound
Description: Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
Study: NCT02851628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternative sizing model based trial mask
Description: A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
Study: NCT02791009

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.

Intervention type: OTHER
Intervention: Electrocardiogram (ECG)
Description: ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Study: NCT02851628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype Full Face Mask
Description: A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
Study: NCT02155127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Study: NCT03300726

Intervention type: RADIATION
Intervention: Functional MRI
Description: Functional MRI during resting state and semantic memory task activation

Intervention type: RADIATION
Intervention: Functional MRI
Description: Functional MRI during resting state and semantic memory task activation
Study: NCT01588678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3078a
Description: DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
Study: NCT04208412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: KVD900-matched Placebo Tablet
Study: NCT03347929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: 10 days treatment with Naproxen 500 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days treatment with Placebo1 tablet twice daily
Study: NCT03080272

Intervention type: OTHER
Intervention: no intervention will take place
Description: Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place

Intervention type: OTHER
Intervention: no intervention will take place
Description: Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place

Intervention type: OTHER
Intervention: no intervention will take place
Description: Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place

Intervention type: OTHER
Intervention: no intervention will take place
Description: Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place

Intervention type: OTHER
Intervention: no intervention will take place
Description: Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
Study: NCT03069365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Film-coated tablet
Study: NCT03540446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: First Relief Treatment
Description: To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: First Relief Treatment
Description: To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
Study: NCT02791009

Intervention type: OTHER
Intervention: Electrocardiogram (ECG)
Description: ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.

Intervention type: OTHER
Intervention: Electrocardiogram (ECG)
Description: ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Study: NCT03540446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: First Relief Treatment
Description: To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
Study: NCT02384837

Intervention type: DEVICE
Intervention: EXCEL biodegradable polymer-coated sirolimus-eluting stent

Intervention type: DEVICE
Intervention: EXCEL biodegradable polymer-coated sirolimus-eluting stent
Study: NCT01644461

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
Study: NCT04317547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steering Teens Safe (STS)
Description: The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Feedback Technology.
Description: The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
Study: NCT02594384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM-002A
Description: 25 mg capsules or 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM-002A
Description: 25 mg capsules or 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by vein
Study: NCT02001285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
Study: NCT03845855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Virtual reality with a game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robotic gait
Description: robotic gait therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic gait
Description: robotic gait therapy
Study: NCT00331604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c. After 2 years.